DCVC Bio

We're proud to announce DCVC Bio III: $400 million in fresh capital to support great scientific teams with boundary-pushing ideas for curing disease, extending health-spans, enabling healthy food at lower cost and climate impact, and more! bit.ly/3ZRmdpo

RNA- and DNA-based treatments (gene/cell therapy) have high upfront costs but are curative and more economical than chronic care. Regulators should work with insurers and manufacturers to cover costs and introduce new business models, like gradual payment plans. More in 🧵

We’re seeing a new wave of gene therapy companies developing exquisitely customized viral vectors + other advanced techniques that can deliver therapeutic genes to the body with far more specificity and at much lower doses and cost than before. 👇 dcvc.com/news-insights/…

In the @WSJ, our friend @crisman_ryan, co-founder of @UmojaBiopharma, offers a beautiful example of basic research meandering through labs over decades, then providing learnings that help us reset the immune systems of leukemia + autoimmune patients: on.wsj.com/4aKcN4P

Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025! This award recognizes the companies and innovations pushing science forward to transform the field of life sciences. We're proud of the work we do on behalf of patients, and honored to be included. To learn more: orcabio.com #FierceLifeSciencesAwards and #FierceInnovationAwards

Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies. Read more in the press release: bit.ly/4q1Uzkw #celltherapy #hematology #oncology

How is Grove Biopharma archi­tecting its way around traditional drug limits? Learn from @DCVCBio principal Dr. Emily Park and managing partner @2kstead 👇 (link in 🧵)

@2kstead dcvc.com/news-insights/…

Very exciting progress from Latus Bio! Read more from @DCVCBio Managing Partner @2kstead--link below 👇

Augmented RNA reality is emerging! @creyonbio has the ability to program­mat­i­cally engineer knowably safe and effective siRNAs, ASOs, and other oligo therapies to unlock a huge range of therapeutic advances👇 dcvc.com/news-insights/…

Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/ #BiotechNews #AIinHealthcare

How is @MycoWorksInc scaling its production and simultaneously doing R&D for new mycelium materials? Find out from CEO Matthew Scullin in a great @axios piece from @katiefehren 👇 axios.com/pro/climate-de…

Reishi is here! 🎉 Very exciting progress from @MycoWorksInc, which continues to push the boundaries of sustainable design 👇 fashionunited.in/news/business/…

When one of your portfolio cos is moving toward commer­cial­izing what may be the most conse­quen­tial cancer therapeutic ever, you’re allowed to take a minute to feel excited. That's how we feel today having co-led @UmojaBiopharma's $100m Series C! 🍾 dcvc.com/news-insights/…

We're thrilled to announce that thanks to the most forward-looking investors on the planet, we’ve raised over $700 million for a healthier planet and healthier lives, bringing our total funding closed over the last 2.5 years to over $1.6 billion 🌎🧬🌾 bit.ly/4eHLNl9

Our second annual Deep Tech Opportunities Report is here, offering an extended look at deep tech and how we believe it can help build a future of abundance and resilience. We hope you enjoy it — and the possi­bil­i­ties it signals. dcvc.com/news-insights/…

Great in-depth coverage from @ADeAngelis_bio @statnews about our announcement of DCVC Bio III: $400 million in fresh capital to continue backing the next generation of companies building breakthrough data-driven life-science businesses.👇 bit.ly/47Q3qgw

Please welcome Serge Messerlian @DCVC, to our Board of Directors! With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs. brnw.ch/21wMua9